Literature DB >> 15533905

How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk?

Maurice P Zeegers1, Lambertus A L M Kiemeney, Alan M Nieder, Harry Ostrer.   

Abstract

OBJECTIVE: Although narrative reviews have suggested an association between (CAG)n and (GGN)n polymorphisms in the AR gene and prostate cancer, it has never been quantified systematically. The purpose of this meta-analysis was to provide relative and absolute quantitative summary estimates with sufficient power.
METHOD: Publications were identified through database searches for epidemiologic studies published until February 2004. For each study, mean differences in repeat length between cases and controls were calculated as well as continuous odds ratios (OR) per one CAG or GGN repeat decrement and discrete ORs to compare prostate cancer risk in men with short CAG repeats (</=21 repeats) versus long CAG repeats (>21 repeats) and short GGN repeats (</=16 repeats) versus long GGN repeats (>16 repeats). The study-specific estimates were combined by random effects metaregression analyses.
RESULTS: Nineteen case-control studies were included in this review comprising a total of 4,274 cases and 5,275 controls. Prostate cancer cases had on average 0.26 fewer CAG repeats and 0.09 fewer GGN repeats than controls. The continuous ORs of prostate cancer per one repeat decrement were 1.02 and 1.01 for CAG and GGN repeats, respectively. The summary discrete OR (95% confidence interval) were 1.19 (1.07-1.31) and 1.31 (1.06-1.61) for CAG and GGN repeat polymorphisms, respectively.
CONCLUSION: Although the presence of shorter repeats seemed to be modestly associated with prostate cancer risk, the absolute difference in number of repeats between cases and controls is <1 repeat. We question whether such a small difference is enough to yield measurable biological impact in prostate carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15533905

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  33 in total

1.  A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.

Authors:  Sara Lindström; Jing Ma; David Altshuler; Edward Giovannucci; Elio Riboli; Demetrius Albanes; Naomi E Allen; Sonja I Berndt; Heiner Boeing; H Bas Bueno-de-Mesquita; Stephen J Chanock; Alison M Dunning; Heather Spencer Feigelson; J Michael Gaziano; Christopher A Haiman; Richard B Hayes; Brian E Henderson; David J Hunter; Rudolf Kaaks; Laurence N Kolonel; Loic Le Marchand; Carmen Martínez; Kim Overvad; Afshan Siddiq; Meir Stampfer; Pär Stattin; Daniel O Stram; Michael J Thun; Dimitrios Trichopoulos; Rosario Tumino; Jarmo Virtamo; Stephanie J Weinstein; Meredith Yeager; Peter Kraft; Matthew L Freedman
Journal:  J Clin Endocrinol Metab       Date:  2010-06-09       Impact factor: 5.958

2.  Identification of a novel germline missense mutation of the androgen receptor in African American men with familial prostate cancer.

Authors:  Si-Yi Hu; Tao Liu; Zhen-Zhen Liu; Elisa Ledet; Cruz Velasco-Gonzalez; Diptasri M Mandal; Shahriar Koochekpour
Journal:  Asian J Androl       Date:  2010-02-22       Impact factor: 3.285

3.  Decision tree-based modeling of androgen pathway genes and prostate cancer risk.

Authors:  Jill S Barnholtz-Sloan; Xiaowei Guan; Charnita Zeigler-Johnson; Neal J Meropol; Timothy R Rebbeck
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-04-14       Impact factor: 4.254

Review 4.  Genetic susceptibility to cancer: the role of polymorphisms in candidate genes.

Authors:  Linda M Dong; John D Potter; Emily White; Cornelia M Ulrich; Lon R Cardon; Ulrike Peters
Journal:  JAMA       Date:  2008-05-28       Impact factor: 56.272

Review 5.  Molecular mechanisms involving prostate cancer racial disparity.

Authors:  Cansu Karakas; Cassie Wang; Fangming Deng; Hongying Huang; Dongwen Wang; Peng Lee
Journal:  Am J Clin Exp Urol       Date:  2017-11-09

Review 6.  Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview.

Authors:  S Salvi; V Conteduca; G Gurioli; D Calistri; V Casadio; U De Giorgi
Journal:  Mol Diagn Ther       Date:  2016-02       Impact factor: 4.074

7.  Testosterone and prostate health: Have the paradigms truly shifted?

Authors:  Alvaro Morales; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2020-08       Impact factor: 1.862

Review 8.  Shorter GGN Repeats in Androgen Receptor Gene Would Not Increase the Risk of Prostate Cancer.

Authors:  Jiatong Li; Feifan Xiao; Yuening Zhang; Aihua Lan; Qian Song; Ruoheng Zhang; Kailong Gu; Ping Chen; Zhuo Li; Xinhua Zhang; Xiaoli Yang
Journal:  Technol Cancer Res Treat       Date:  2016-10-17

9.  Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.

Authors:  Jie Li; Emma Mercer; Xin Gou; Yong-Jie Lu
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

10.  Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene.

Authors:  Liang Huo; Richard E Straub; Catherine Roca; Peter J Schmidt; Kai Shi; Radhakrishna Vakkalanka; Daniel R Weinberger; David R Rubinow
Journal:  Biol Psychiatry       Date:  2007-06-27       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.